Based on our study results, we concluded that BH substantially suppressed Notch3 signaling in human lung cancer, resulting in powerful antitumor activity in human lung cancer both in vitro and in vivo, and that it can improve the sensitivity of resistant NSCLC to gefitinib. The gene discussed is NOTCH3; the disease is non-small cell lung carcinoma.